Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02007044 · ClinicalTrials.gov registry record · Phase 2

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

A Phase 2 study of Recurrent Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
66
Enrollment target
1
Study location

NCT02007044 is a Phase 2 study of Recurrent Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 66 participants, above the 46-participant average among 20 other Recurrent Chronic Lymphocytic Leukemia trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02007044, a Phase 2 study of Recurrent Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies ibrutinib with or without rituximab in treating patients with chronic lymphocytic leukemia that has come back after treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether ibrutinib is more effective with or without rituximab in treating chronic lymphocytic leukemia.

Conditions Studied

Recurrent Chronic Lymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Prolymphocytic Leukemia

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • BIOLOGICAL Rituximab
  • DRUG Ibrutinib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2013-12-06
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02007044

The ClinicalTrials.gov registry entry for NCT02007044 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 20 other Recurrent Chronic Lymphocytic Leukemia trials with a reported enrollment target (43% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT02007044 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02007044 about?

NCT02007044 is a clinical study titled "Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia". This phase II trial studies ibrutinib with or without rituximab in treating patients with chronic lymphocytic leukemia that has come back after treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, s...

What is the current status of trial NCT02007044?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2013-12-06. Estimated completion is 2026-06-30.

What conditions does trial NCT02007044 study?

This clinical trial studies the following conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Prolymphocytic Leukemia.

What interventions are being tested in trial NCT02007044?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Rituximab (BIOLOGICAL), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT02007044?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02007044 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Chronic Lymphocytic Leukemia

All registered trials for this condition

Recurrent Small Lymphocytic Lymphoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.